Atlas Trials

Primary Myelofibrosis (PMF)

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Primary Myelofibrosis (PMF)

RecordFirmDate
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis (NCT04878003)Kartos Therapeutics, Inc.2021-04-13
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (NCT04676529)Syntara2021-02-18
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis (NCT04217993)Suzhou Zelgen Biopharmaceuticals Co.,Ltd2020-01-07
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (NCT03935555)Samus Therapeutics, Inc.2019-08-12
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (NCT03662126)Kartos Therapeutics, Inc.2019-01-15
Extended Access of Momelotinib in Adults With Myelofibrosis (NCT03441113)GlaxoSmithKline2018-05-03
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) (NCT03136185)Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)2017-07-18
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (NCT02515630)Sierra Oncology LLC - a GSK company2016-01-29
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (NCT02101268)Sierra Oncology LLC - a GSK company2014-06-19
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (NCT01558739)Novartis Pharmaceuticals2012-05-01
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (NCT00910728)AstraZeneca2009-05-01
Managed Access Programs for INC424, Ruxolitinib (NCT04745637)Novartis Pharmaceuticals

Track Primary Myelofibrosis (PMF) automatically

Every clearance here is in the API, with alerts when new ones post.